Aurobindo Pharma Limited has informed the Exchange about General Updates
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma has informed stock exchanges that the US FDA has classified Unit-II of its wholly owned subsidiary Eugia Pharma Specialities Limited, located in Bhiwadi, Rajasthan, as 'Official Action Indicated' (OAI). The facility was inspected from November 3 to November 14, 2025, and received a Form 483 with 9 observations at the end of the inspection. OAI is the most serious of the FDA's three inspection classifications and typically indicates that regulatory action such as a warning letter or import alert may follow. The company has stated that it does not currently foresee any impact on its business and is committed to maintaining quality standards.
This is a negative regulatory development that could potentially affect future US supplies from this facility if the FDA escalates to a warning letter or import alert. Investors should watch for further updates, though the company has downplayed the near-term business impact.